A new DNA immune adsorbent for hemoperfusion in SLE therapy: a clinical trial.
This investigation studied the preparation and clinical trial of DNA immunoadsorbent for hemoperfusion in systemic lupus erythematosus (SLE) therapy. DNA was complexed with blue tetrazolium (BT), then mixed with collodion, and finally adsorbed on macroporous spherical polymeric adsorbent. The percentage of DNA thus immobilized was 98-98.5%, and no release was detected during hemoperfusion. A patient with severe SLE was treated with the above adsorbent in hemoperfusion. The patient was in coma, with high anti-DNA antibody and abnormal immune complex levels, which fell sharply from 56.34% to 0.8% after 2.5 h of whole-blood hemo perfusion. There were no major clinical complications, and 2 weeks later, her proteinuria level became normal and immune complex levels were sustained. She was then discharged from the hospital and has been in good health for more than 1 year.
Yang
Y
Y
Institute of Molecular Biology, Nankai University, Tianjin, China.
Yu
Y T
YT
Song
J C
JC
Qian
S C
SC
Quan
W L
WL
Shao
X H
XH
Cui
R H
RH
Wang
J Z
JZ
D000328:Adult; D000936:Antigen-Antibody Complex / Q000008:administration & dosage*; D004247:DNA / Q000276:immunology*; D005260:Female; D006464:Hemoperfusion / Q000379:methods*; D006801:Humans; D007164:Immunosorbents / Q000008:administration & dosage*; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000628:therapy*
D000936:Antigen-Antibody Complex; D007164:Immunosorbents; D004247:DNA